Pharma Mar, S.A. (BME:PHM)
Spain · Delayed Price · Currency is EUR 83.60
0.00 (0.00%)
Aug 27, 2026, 5:35 PM CET
Pharma Mar Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 218.64 | 221.39 | 174.86 | 158.15 | 196.34 | 229.83 | |
Revenue Growth | 15.52% | 26.61% | 10.56% | -19.45% | -14.57% | -14.87% |
Cost of Revenue | 14.47 | 12.26 | 8.18 | 9.61 | 13.64 | 16.44 |
Gross Profit | 204.17 | 209.13 | 166.67 | 148.54 | 182.7 | 213.39 |
Selling, General & Admin | 63.44 | 59.38 | 47.18 | 41.81 | 43.24 | 39.74 |
Research & Development | 94.98 | 95.19 | 103.5 | 99.3 | 83.45 | 72.17 |
Other Operating Expenses | 6.89 | -6.15 | 9.52 | 11.26 | 13.94 | 9.04 |
Operating Expenses | 165.31 | 148.42 | 160.2 | 152.37 | 140.63 | 120.95 |
Operating Income | 38.87 | 60.72 | 6.47 | -3.83 | 42.07 | 92.45 |
Interest Expense | -0.84 | -2.46 | -2.47 | -2.42 | -2.38 | -3.37 |
Interest & Investment Income | 4.83 | 3.44 | 5.68 | 4.32 | 0.88 | 0.37 |
Currency Exchange Gain (Loss) | -2.05 | -2.05 | 2.31 | -1.68 | 3.11 | 5.67 |
EBT Excluding Unusual Items | 40.81 | 59.65 | 11.99 | -3.61 | 43.68 | 95.12 |
Gain (Loss) on Sale of Investments | - | - | - | -0.02 | -1.89 | 0.01 |
Other Unusual Items | - | - | - | - | 2 | - |
Pretax Income | 40.81 | 59.65 | 11.99 | -3.62 | 43.79 | 95.13 |
Income Tax Expense | -15.32 | -15.34 | -14.14 | -4.76 | -5.57 | 2.27 |
Earnings From Continuing Operations | 56.13 | 74.99 | 26.13 | 1.14 | 49.36 | 92.86 |
Net Income to Company | 56.13 | 74.99 | 26.13 | 1.14 | 49.36 | 92.86 |
Net Income | 56.13 | 74.99 | 26.13 | 1.14 | 49.36 | 92.86 |
Net Income to Common | 56.13 | 74.99 | 26.13 | 1.14 | 49.36 | 92.86 |
Net Income Growth | 33.61% | 187.03% | 2197.71% | -97.70% | -46.85% | -32.35% |
Shares Outstanding (Basic) | 18 | 17 | 18 | 18 | 18 | 18 |
Shares Outstanding (Diluted) | 18 | 17 | 18 | 18 | 18 | 18 |
Shares Change | 3.57% | -0.62% | -1.98% | -0.81% | -0.12% | -1.31% |
EPS (Basic) | 3.11 | 4.30 | 1.49 | 0.06 | 2.73 | 5.14 |
EPS (Diluted) | 3.11 | 4.30 | 1.49 | 0.06 | 2.73 | 5.13 |
EPS Growth | 29.14% | 188.68% | 2382.56% | -97.80% | -46.78% | -31.51% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 54.02 | 46.67 | -8.99 | -28.25 | 29.47 | 17.87 |
Free Cash Flow Per Share | 2.99 | 2.67 | -0.51 | -1.58 | 1.63 | 0.99 |
Dividend Per Share | 1.000 | 1.000 | 0.800 | 0.650 | 0.650 | 0.650 |
Dividend Growth | 25.00% | 25.00% | 23.08% | 0% | 0% | 8.33% |
Gross Margin | 93.38% | 94.46% | 95.32% | 93.92% | 93.05% | 92.85% |
Operating Margin | 17.78% | 27.42% | 3.70% | -2.42% | 21.43% | 40.22% |
Profit Margin | 25.67% | 33.87% | 14.94% | 0.72% | 25.14% | 40.40% |
Free Cash Flow Margin | 24.71% | 21.08% | -5.14% | -17.87% | 15.01% | 7.78% |
EBITDA | 44.83 | 66.47 | 10.07 | -1.15 | 44.88 | 94.99 |
EBITDA Margin | 20.50% | 30.02% | 5.76% | -0.73% | 22.86% | 41.33% |
D&A For EBITDA | 5.96 | 5.75 | 3.6 | 2.68 | 2.81 | 2.54 |
EBIT | 38.87 | 60.72 | 6.47 | -3.83 | 42.07 | 92.45 |
EBIT Margin | 17.78% | 27.42% | 3.70% | -2.42% | 21.43% | 40.22% |
Effective Tax Rate | - | - | - | - | - | 2.39% |
Revenue as Reported | 221.39 | 221.39 | 174.86 | 158.15 | 196.34 | 229.83 |